Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Invesco WilderHill Clean Energy ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Invesco WilderHill Clean Energy ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.22 (market cap $29.60B), while Invesco WilderHill Clean Energy ETF trades at $35.46. The key difference: Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYPBW
Market Cap
$29.60B
Sector
HealthSector/Thematic
52-Week High
$491.22$46.99
52-Week Low
$205.48$24.14
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

Invesco WilderHill Clean Energy ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Invesco WilderHill Clean Energy ETF

PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.

Read more on PBW